Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05568225 · ClinicalTrials.gov registry record · Phase 2
A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
A Phase 2 study, sponsored by Forma Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT05568225 is a Phase 2 study that was terminated before completion, run by Forma Therapeutics. The registered enrollment target is 17 participants.
The verdict
NCT05568225, a Phase 2 study, was terminated before completion, sponsored by Forma Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of etavopivat (FT-4202) for the treatment of anemia in adult patients with very low risk, low risk, or intermediate risk MDS.
Interventions
- DRUG Etavopivat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2022-11-15 |
| Est. Completion | 2024-07-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05568225
The ClinicalTrials.gov registry entry for NCT05568225 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forma Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Etavopivat is the first listed.
NCT05568225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05568225 about?
NCT05568225 is a clinical study titled "A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)". The purpose of this study is to evaluate the safety and efficacy of etavopivat (FT-4202) for the treatment of anemia in adult patients with very low risk, low risk, or intermediate risk MDS.
What is the current status of trial NCT05568225?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2022-11-15. Estimated completion is 2024-07-15.
What interventions are being tested in trial NCT05568225?
The interventions under investigation include: Etavopivat (DRUG).
Who is sponsoring clinical trial NCT05568225?
This trial is sponsored by Forma Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.